November 17, 2015
LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that it has signed a global agreement with WuXi NextCODE to provide clinical and scientific evidence for delivering the best personalized treatment options based on the results of WuXi NextCODE tumor-normal genome sequence interpretation, which identifies key driver mutations in individual tumors. Financial terms of the agreement are not disclosed.
WuXi NextCODE manages and interprets more genomes than any other system in the world. It is deploying its unique database, informatics and reporting system for major precision medicine efforts in the UK, US, China, Qatar and elsewhere – in cancer, rare disease, and drug discovery and development.
N-of-One clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient's specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient.
The global agreement between the companies enables them to collaborate on WuXi NextCODE's work with the UK 100,000 Genomes Project and to tailor offerings for other geographies in the months ahead.
"We are very pleased to be able to offer N-of-One solutions to our cancer diagnostics partners," said Hannes Smarason, co-founder, president and COO of WuXi NextCODE. "Through our work in China, the US and Europe we are making it possible to efficiently identify the molecular drivers of individual tumors, and N-of-One provides the latest scientific and clinical evidence to enable clinicians to find the treatments best suited to each patient."
"N-of-One is very pleased to be working closely with WuXi NextCODE to deliver a best-in-class, patient-specific solution to the market,"said Chris Cournoyer, CEO at N-of-One. "Our objective is to continue to provide high-quality, patient-specific clinical interpretation evidence at a cost-effective price and through our partnership with WuXi to extend our reach globally."
About WuXi NextCODE
WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world's leading genome interpretation and research system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivalled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to diagnose, treat and prevent disease. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.
N-of-One, a leader in enabling precision medicine for oncology, leverages its world-class team of experts coupled with a highly proprietary platform that allows us to provide clinical solutions and services, such as molecular interpretation, to clinicians at the point of care. N-of-One's team of experts has interpreted thousands of samples for oncologists and patients worldwide, through partnerships with leading diagnostic companies, hospital systems, directly to oncologists and through employee access benefit programs. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.